Virtual Library

Start Your Search

Y. Yang



Author of

  • +

    ORAL 05 - Surgery (ID 97)

    • Event: WCLC 2015
    • Type: Oral Session
    • Track: Treatment of Locoregional Disease – NSCLC
    • Presentations: 1
    • +

      ORAL05.07 - Mediastinal Lymphadenectomy Fulfilling NCCN Criteria May Improve the Outcome of Clinical N0-1 and Pathological N2 Non-Small Cell Lung Cancer (ID 692)

      10:45 - 12:15  |  Author(s): Y. Yang

      • Abstract
      • Presentation
      • Slides

      Background:
      Individual academic societies have published different recommendations about definitions and requirement of nodal assessment. It's generally agreed that radical mediastinal lymphadenectomy will provide accurate information for pathological staging and guiding adjuvant therapy. However it is not clearly established whether mediastinal lymphadenectomy compliant with international criteria will improve the oncological outcomes of clinical early-stage lung cancer. This retrospective study was aimed to compare the long-term survival between the cases treated with lymphadenectomy fulfilling the NCCN criteria and other cases not met the criteria in clinical early-stage lung cancer patients.

      Methods:
      During the investigation period, 712 consecutive cases of clinical N0/1 entered the analysis, confirming as 152 cases of pN2 (pathological N2) and 560 of pN0-1 (pathological N0-1) disease after surgery. Group A was defined as the cases fulfilling the National Comprehensive Cancer Network (NCCN) lymphadenectomy criteria (≥three stations of N2 nodes dissection) and Group B was those who did not meet the criteria. Two groups were stratified by pN status and the outcomes were analyzed and multivariate Cox regression was performed to determine prognostic factors.

      Results:
      5-year Overall survival (OS) and 5-year disease-free survival (DFS) were significantly different between two groups at cN0/1-pN2 status (5-year OS rates, 50±5% vs. 25±9%, p=0.006; 5-year DFS rates, 31.0±4% vs. 13±7%, p=0.014), but not at pN0-1 status (Figure 1). T staging and lymphadenectomy fulfilling NCCN criteria were prognostic factors in cN0/1-pN2 group by multivariate regression analysis. Furthermore, the cases treated with ≥ 4 stations of mediastinal lymph nodes dissection could not achieve better survival benefit compared to those harvesting 3 stations of N2 node in cN0/1-pN2 group (the 5-year OS rates, 46±6% vs. 59±9%, p=0.152).The spreading pattern of mediastinal nodes among pN2 cases was featured by tumor location. The most frequent involved station for right upper lobe-located lung cancer was 4R (83.7%), followed by 7 (37%) and 2R (14.0%). The top 3 involved stations for other cancer locations were 7 (75%), 4R (25%) and 2R (6.3%) for right middle lobe; 7 (81.6%), 4R (34.2%) and 2R (10.5%) for right lower lobe; 5+6 (90.9%), 4L (22.7%) and 7 (4.5%) for left upper lobe; 7 (66.7%), 5+6 (42.4%) and 8 (9.1%) for left lower lobe. Figure 1



      Conclusion:
      Mediastinal lymphadenectomy fulfilling with NCCN criteria may only improve the survival of pathological upstaging subgroup (cN0/1-pN2) among patients with clinical early-stage lung cancer. More extended dissection of mediastinal lymph node (≥ 4 stations) may not further improve the outcome in this group.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P2.01-028 - Neoadjuvant Crizotinib and Surgical Resection of Two Stage IIIA Lung Adenocarcinomas with Anaplastic Lymphoma Kinase Gene Rearrangement (ID 3150)

      09:30 - 17:00  |  Author(s): Y. Yang

      • Abstract
      • Slides

      Background:
      Neoadjuvant therapy is also known as induction therapy or preoperative therapy. For lung cancer, the neoadjuvant medication includes chemotherapy and targeted medication. Neoadjuvant chemotherapy is widely used in clinical practices, but targeted therapy is still rare in the preoperative applications. To our knowledge, this is the first report of neoadjuvant crizotinib and following surgery of pulmonary adenocarcinoma.

      Methods:
      Crizotinib had already been recommend as the standard treatment for advanced lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangement. First-line therapy with crizotinib prolonged progression-free survival and improved qulity of life among selected patients. The possibility of using crizotinib as neoadjuvant therapy is interesting because of low toxicity of tyrosine kinase inhibitors. Here we report two cases affected by locally advanced lung adenocarcinoma, in whom one-month crizotinib treatment rendered the tumors reduction to surgical removal.

      Results:
      These two patients with ALK-positive stage IIIA received oral crizotinib 250mg twice daily in thirty days, and crizotinib was well tolerated with rapid, prominent responses following by surgery in a week. The sequential therapy of case 1 showed the less adverse events in crizotinib than chemotherapy, while case 2 revealed more obvious responses.

      Conclusion:
      For pulmonary adenocarcinoma patients with ALK rearrangement, crizotinib could achieve a higher remission rate and less adverse events as compared with the chemotherapy, suggesting that crizotinib may be better option for neoadjuvant therapy. A propositional clinical trial exploring the ability of preoperative crizotinib to achieve better results than can be obtained with chemotherapy in patients selected on the basis of ALK gene rearrangement is urgently needed.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.